The Safety and Immunogenicity of a Cell-Derived Adjuvanted H5N1 Vaccine – A Phase I Randomized Clinical Trial
ConclusionsThis Phase I trial showed the MDCK-derived H5N1 candidate vaccine is safe and immunogenic. The source of RBCs has a significant impact on the measurement of HAI titers (ClinicalTrials.gov number: NCT01675284.).
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research
More News: Allergy & Immunology | Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Clinical Trials | Flu Pandemic | H5N1 | Influenza | Influenza Vaccine | Microbiology | Middle East Health | Pain | Pandemics | Turkey Health | Urology & Nephrology | Vaccines